Stay Up to Date
with SHINE

Why an Offline Nuclear Reactor Led to Thousands of Hospital Appointments Being Canceled

CNN- The US is on the cusp of a nuclear renaissance. One problem: Americans are terrified of the waste

Explore how n.c.a. lutetium-177-based therapy precisely targets and treats cancer using radioactive properties. Learn about its unique ability to destroy cancer cells while minimizing damage to healthy tissue.

Early research on cancer drugs that use SHINE Technologies’ Illumira product found they could extend patients’ lifespans and more effectively treat kidney and prostate cancer, the Janesville company announced.

University Medical Center Groningen’s collaboration with SHINE aims to advance cancer research and secure the medical supply chain of critical isotopes in Europe

The two organizations join forces to improve global access to radiopharmaceutical therapy, with the Oncidium foundation aiming to provide 2,000 doses in five years through the initiative

University Medical Center Groningen’s collaboration with SHINE aims to advance cancer research and secure the medical supply chain of critical isotopes in Europe

Pre-clinical research results show that WARF Therapeutics’ WT-7695 radiopharmaceutical, which uses SHINE’s Ilumira, achieved 100% survival in a model of kidney cancer. ART-101, a novel prostate cancer treatment developed at the Advanced Radiotheranostics Lab using SHINE’s Ilumira, demonstrates superior efficacy compared to current therapies

SHINE receives a second grant from the Department of Energy’s Small Business Innovation Research project, supporting its Phase 3 efforts to recycle nuclear waste.

Glytherix Ltd announced today a new global clinical supply agreement with SHINE Technologies for non-carrier added lutetium-177 (n.c.a. Lu-177)

Our team joined hundreds of community members at the Town Square Pavilion for the 31st annual walk. This year, thanks to the incredible generosity of our employees and vendors, we raised over $8,600 for the American Heart Association

Transformational leaders join SHINE to guide the company through next stages of growth and profitability

TOFE 2024 spotlights fusion's future: collaboration is key, near-term value creation crucial. Industry leaders, including SHINE, discuss workforce challenges and simplifying fusion tech. Dive into insights shaping our industry's path forward.

AuntMinnie- The European Commission has approved a $2.17 billion proposal by the Netherlands to fund construction of a new medical isotope production facility in Petten.

U.S.-based SHINE Technologies has been awarded $32M from the Department of Energy’s National Nuclear Security Administration (DOE/NNSA).